Skip to main content
. 2020 Apr 6;10(12):5322–5340. doi: 10.7150/thno.42371

Figure 4.

Figure 4

PEX5 was upregulated in HCC tissues. (A-B) The PEX5 protein level was upregulated in HCC tissue, as shown by immunohistochemical analysis of a tissue microarray (n = 169, ***P < 0.001). (C) Nuclear positive rate of PEX5 in HCC tissues and paratumor tissues (n = 169, ***P < 0.001). (D) Association between the nuclear positive rate of PEX5 and clinical stage of HCC (n = 169, **P < 0.01). (E-F) Association between the protein level or nuclear positive rate of PEX5 and overall survival (n = 169, *P < 0.05, **P < 0.01). (G) The PEX5 mRNA level in 12 paired HCC specimens was measured by qRT-PCR (n = 12). (H) Representative image of PEX5 IHC in a sample from patient 157. The nuclear and cytoplasmic levels of PEX5 in HCC tissue were higher than those in normal tissue. (I) PEX5 protein level in 12 paired HCC specimens, as shown by WB. (J) Negative relationship between the PEX5 and miR-31-5p expression levels (Spearman correlation analysis, r=-0.7762, P=0.003). (K) High mRNA expression of PEX5 in HCC tissues (ONCOMINE database) (*P<0.05). (L) High mRNA expression of PEX5 in HCC tissues (GEO dataset) (*P<0.05). (M) PEX5 mRNA expression levels in HCC patients with tumors of different pathological grades (Edmondson-Steiner Grade, ONCOMINE database) (**P<0.01, ***P<0.001). (N) PEX5 mRNA expression levels in HCC patients at different clinical stages. (Barcelona Clinic Liver Cancer stage, ONCOMINE database) (*P<0.05). Patients with advanced-stage disease had high PEX5 mRNA levels. (O) Overall survival of HCC patients with high and low PEX5 expression levels. (P=0.041; LinkedOmics database, Kaplan-Meier survival analysis). Patients with high PEX5 levels had poor survival outcomes. Abbreviations: T, tumor tissues; N, normal tissues; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.